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ABSTRACT 
There is a concern that bisphosphonates may impair fracture healing due to their inhibitory 
effects on bone turnover. Here we evaluated the effects of early bisphosphonate therapy on 
fracture healing and functional outcome following a fracture of the distal radius. The fracture 
and bisphosphonates (FAB) trial was a double blind, randomized placebo-controlled trial 
involving 15 trauma centres in the UK. We enrolled 421 bisphosphonate naïve patients aged 
≥50 years with a radiographically confirmed fracture of the distal radius and randomised them 
in a 1:1 ratio to receive alendronic acid 70mg once weekly (n=215) or placebo (n=206) within 
14 days. The primary outcome measure was the proportion of fractures that had 
radiologically united at 4-weeks as assessed by an observer, blinded to treatment allocation. 
Secondary outcomes included the Disability Arm Shoulder and Hand (DASH) questionnaire, 
range of wrist movement and grip strength, pain and analgesia requirements and the rate of 
malunion. The mean (±SD) age of participants was 63 ± 8.5 years and 362 (86%) were female. 
At 4 weeks, 48/202 (23.8%) of fractures had united in the alendronic acid group compared 
with 52/187 (27.8%) in the placebo group (observed mean difference 4.0%; 95% CI -4.7% to 
12.8%; p=0.36). The mean difference between groups based on imputed data was 4.5% (95% 
CI -4.7% to 13.8%; p=0.30). There was no significant difference in the proportion of fractures 
that had united at any other timepoint and no differences in the DASH score, pain at the 
fracture site, grip strength or any other clinical outcome. We conclude that among patients 
aged 50 and above with a distal radius fracture, early administration of alendronic acid does 
not adversely affect fracture union or clinical outcome.  These findings suggest 
bisphosphonate therapy can be safely commenced early after fracture if clinically indicated. 
Trial registration: EudraCT (2011-000988-28) and ISRCTN (62133820). 
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INTRODUCTION 
Bisphosphonates are widely used in the treatment of osteoporosis(1) and amongst the 
bisphosphonates, alendronic acid is the most frequently prescribed drug(2).  Bisphosphonates 
have powerful inhibitory effects on bone remodelling(3), a process that is critically important 
for fracture healing (4).  Because of this, there is a theoretical concern that bisphosphonates 
may inhibit union and adversely affect other outcomes following a fracture(5,6). Delayed 
fracture union has been observed in observational studies of patients being treated with 
bisphosphonates(7). Due to uncertainty about the effects of bisphosphonate on fracture 
healing, many clinicians are reluctant to start bisphosphonate therapy immediately following 
a fracture because of concerns that clinical outcome may be compromised and prefer to wait 
until the fracture has healed before commencing treatment.  
Robust evidence on the effects of bisphosphonates on fracture healing is lacking. This 
is of clinical importance, since if bisphosphonate therapy could be given safely almost 
immediately following a fracture, the protective effect against a second fracture would come 
into play more rapidly than if treatment was delayed for 6-8 weeks. This is highly relevant 
since the risk of a second fracture increases greatly after an incident fracture(8,9).  
The aim of this multi-centre, double blind randomized placebo-controlled trial was to 
determine if the early introduction of treatment with alendronic acid influences fracture 
healing or other relevant clinical outcomes in patients aged 50 years or over who have 
sustained a fracture of the distal radius.  
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METHODS 
The fractures and bisphosphonates (FAB) trial was a multi-centre, double blind, parallel-group 
randomized placebo-controlled trial in which participants were randomized in a 1:1 ratio to 
receive oral alendronic acid or placebo.  All participants gave written informed consent before 
enrolment and the trial was approved by the East of Scotland Research Ethics Committee and 
regulatory authority in the United Kingdom (REC No. 11/AL/0319).  A total of 15 centres across 
the UK took part in the study.   
Patients 
Between April 2012 and November 2015, 8707 patients aged ≥50 years that had presented 
with radiographically confirmed extra-articular or minimal articular fractures of the distal 
radius at 15 UK trauma centres were screened for inclusion into the study (Figure 1).  Patients 
were excluded if they had been treated with bisphosphonates in the previous two years, or 
had been treated with strontium ranelate, calcitonin, denosumab, parathyroid hormone or 
systemic glucocorticoids within the previous 6 months. Those with a previous fracture on the 
same side, bilateral fractures or a pathological fracture were also excluded, as were those 
with contraindications to alendronic acid such as impaired renal function (eGFR <35), 
hypocalcaemia or swallowing difficulty. Recruitment was stopped on the advice of the trial 
steering committee when 421 patients had been enrolled since this was expected to provide 
sufficient power to meet the primary endpoint.  
Randomization 
Randomization was based on a computer-generated list created by Edinburgh Clinical Trials 
Unit and was stratified by study centre, gender and fracture characteristics (undisplaced or 
displaced). Each section was built up of 200 blocks and each block was randomly determined 
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to be of size two or four. Participants and investigators were blinded to the randomization 
allocation. 
Baseline investigations and assessments  
Baseline demographic data and injury characteristic data were collected at the time of 
enrolment along with information on smoking, alcohol intake and co-morbidities. The 
Charlson score was used to quantitate clinical co-morbidity(10).  At baseline the Disabilities of 
the Arm and Shoulder (DASH) questionnaire(11) was administered retrospectively to assess 
upper limb function immediately prior to the injury. A venous blood sample was taken for 
measurement of renal function, calcium and albumin concentrations.  
Treatment allocation 
Study medication was commenced within 14 days of the fracture and 7 days of 
randomization. The mean ( SD) time between sustaining the fracture and starting study 
medication was 10.2  3.3 days in the alendronic acid group and 10.4  2.2 days in the placebo 
group with a minimum time of 2 days in each group and a maximum of 18 days in the 
alendronic acid and 17 days in the placebo group. Patients were prescribed 70mg of oral 
alendronic acid or a matching placebo once weekly for 24 weeks and advised to take the 
medication after an overnight fast with at least 100ml water and to leave at least 30 minutes 
before taking other medication or food. Participants were asked to bring their medication at 
each study visit and adherence was assessed through discussion and pill counts.  Telephone 
consultations were conducted at 16 and 24 weeks to evaluate adherence, use of concomitant 
medications and adverse events.  
Outcome measures 
The primary outcome measure was fracture union at 4 weeks assessed by analysis of 
anteroposterior (AP) and lateral wrist radiographs. The radiographs were analysed by an 
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experienced observer (MMQ) who was blinded to treatment allocation and the order in which 
radiographs were taken. A random sample of 10% of all radiographs (n=154) were double 
read by another observer (ADD) as a quality check. In this random sample there was 
agreement on healing status in 130/154 radiographs (84.4%) such that 35 fractures were 
considered by both observers to have healed and 95 fractures not to have healed. There as 
disagreement in 24 fractures (15.6%) such that 10 fractures that were considered by ADD to 
have healed were considered not to have healed by MMQ and 14 fractures that were 
considered by MMQ to have healed were considered not to have healed by ADD. The overall 
agreement between observers for fracture healing in this analysis had a Kappa value of 0.63 
(substantial; 95% CI 0.50-0.77).  
The Arbeitsgemeinschaft für Osteosynthesefragen (AO) – Orthopaedic Trauma 
Association (OTA) classification for distal radius fractures was used to classify all fractures (12).  
The initial radiograph was assessed for evidence of fracture comminution (yes or no), dorsal 
angulation (degrees), carpal alignment (yes or no) and ulnar variance (mm) using standardised 
methods (13).  Carpal malalignment was defined to be present if the long axes of the radius 
and capitate were not intersecting within the carpus on the lateral wrist radiograph. Fractures 
were defined as being displaced if there was dorsal angulation >10 degrees, ulnar variance >3 
mm, carpal malalignment or a combination of the three features. 
Fractures were defined as united when there was bridging of three out of four 
cortices; evidence of endosteal healing; and 75% organised trabecular bridging at the fracture 
site essentially as described (14).  Malunion was assessed at the 26-week visit by measuring 
dorsal angle, carpal alignment, and radial shortening and was defined to exist when there was 
carpal mal-alignment with less than neutral dorsal tilt and/or more than 3mm of radial 
shortening.   
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Secondary outcome measures included the DASH questionnaire, wrist range of 
movement, grip strength, pain at the fracture site, analgesic use and the presence of Chronic 
Regional Pain Syndrome type 1 (CRPS).  Flexion and extension at the wrist and distal radio-
ulnar joint was assessed by 17cm half circle goniometer whereas pronation, supination, radial 
and ulnar deviation were assessed using a 20cm full circle goniometer. Grip strength was 
assessed using a JAMAR digital hand dynamometer (Patterson Medical, IL, USA).  Assessments 
of range of movement and grip strength were made on the affected and contralateral side in 
triplicate and the mean value calculated. Range of movement and grip strength were 
expressed as the percentage deficit in the fractured side compared with the contralateral 
side. Pain at the fracture site was assessed using a 11-point rating scale (0 = no pain; 10 = 
worst pain imaginable).  Analgesic use in the 24 hours preceding the visit was recorded.  
Assessment for the presence of CRPS was performed at 6 and 26 weeks using a tool based on 
the International Association for the Study of Pain’s (IASP) Budapest Criteria (15).   
Clinical care 
Management of the fracture was carried out according to normal clinical practice and 
included; below elbow cast immobilisation with or without manipulation under anaesthesia 
(MUA); MUA with K-wires, (non-) bridging external fixation with or without K-wires; or open 
reduction and internal fixation (ORIF). Use of analgesics, other medications and 
physiotherapy were carried out according to normal clinical practice. 
Study power and statistical analysis 
We calculated that 250 patients per group would provide more than 90% power to detect a 
15% difference in the proportion of patients who had a healed fracture at 4 weeks after the 
injury, irrespective of the actual proportion of patients in the placebo group whose fracture 
had healed. Since the research question can be thought of as being analogous to a non-
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inferiority comparison, the implications of using the proposed sample for a non-inferiority 
analysis was also explored based on a previous trial which investigated the effects of ascorbic 
acid on fracture healing (16). In that study the mean ( SD) time to radiological healing in 
undisplaced distal radial fractures was 42  13 days. Based on that we considered that a 10% 
margin of inferiority (4 days) would not be clinically significant. The above sample size 
provided 97% power to demonstrate non-inferiority assuming the treatments were 
equivalent and 86% power to demonstrate non-inferiority assuming that the true mean delay 
in healing was up to one day.  The actual sample size of 421 patients provided at least 84% 
power to detect the pre-specified 15% difference in the primary endpoint based on a 
superiority design.  
The data were analysed using the intention to treat principle, irrespective of whether 
the actual intervention complied with the allocated intervention.  The primary outcome of 
the proportion of fractures healed at 4 weeks was compared between the groups using 
logistic regression analysis with adjustment for the variables used in the randomization 
algorithm and variables known to influence fracture outcome (age, comminution and ulnar 
variance on the initial radiograph) in order to maximise power (17). These results are presented 
as an adjusted odds ratio with the corresponding 95% confidence intervals (CI).  As 
radiographs were missing for more than 5% of cases at 4 weeks with which to assess fracture 
healing, the primary analysis used multiple imputation (100 imputations were obtained) and 
the complete case analysis was performed as a sensitivity analysis. 
For the primary outcome, missing data was handled in two stages. If no radiograph 
was available at 4-weeks, it was assumed that the fracture had healed, if the radiographs at 
2-weeks had shown fracture healing.  If the 6-week or 8-week radiographs had not shown 
healing, then it was assumed that the fracture had not healed at 4-weeks.  If, after this first 
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stage, there were still >5% of subjects with missing data then the primary analysis of fracture 
healing used multiple imputation, using the baseline covariates set out above to model the 
probability of fracture healing at the 4-week assessment. An unadjusted analysis of the 
primary outcome measure was also performed.   
Similar analyses were conducted for the secondary outcome measures of radiological 
union at 2, 6 and 8 weeks, as well as CRPS at 6 and 26 weeks (imputation was not required). 
Differences between groups for CRPS were analysed using Fisher’s exact test.   A time to event 
analysis was carried out to evaluate the trajectory of fracture healing from radiographs taken 
at 2, 4, 6 and 8 weeks using the methodology described by So et al. (18)  Analysis of covariance 
was used to compare treatment effects on continuous variables with the models adjusted 
using the variables described above and (if applicable) the corresponding baseline value.  For 
the DASH and pain scores multiple imputation was used for the main analysis at 4 weeks (100 
imputations were obtained) and the complete case analysis was performed as a sensitivity 
analysis.  Statistical significance was set at p<0.05. 
RESULTS 
Disposition and characteristics of study subjects 
The disposition of study subjects is shown in Figure 1. Of the 8707 patients screened, 4913 
(56%) were ineligible. Of the 3794 eligible patients, 421 (11.1%) consented and were 
randomised to receive either alendronic acid 70mg once weekly (n=215) or placebo (n=206) 
(Figure 1). Relevant characteristics of the study population are shown in Table 1. The mean 
age was 63 years and 362 (86%) subjects were female.  The groups were well matched for 
demographic characteristics, medical history, characteristics of the fracture, methods used to 
treat the fracture and previous use of bone active medications, which most commonly were 
calcium and vitamin D supplements and HRT.  
 
 10 
Adherence 
The estimated adherence to study medication based on pill counts and patient interviews 
overall was 85.2% and was similar in the alendronic acid group (85.6%) and placebo group 
(85.0%).  
Primary outcome: radiological fracture union  
The proportion of patients with a united fracture at each time-point is shown in Figure 2. At 
the primary endpoint at 4 weeks, 48/202 (23.8%) of the alendronic acid group had a healed 
fracture compared 52/187 (27.8%) of the placebo group. The adjusted odds ratio, modelled 
using imputed data, was 0.78 (95% CI 0.48 to 1.26; p=0.31). The observed mean difference 
was -4.0% (95% CI, -12.8% to 4.7%; p=0.36), and the corresponding mean difference 
between groups based on imputed data was -4.5% (95% CI -13.8% to 4.7%, p=0.30). There 
was similarly no significant difference between the groups in the proportion of fractures 
healed at other time points; at 2 weeks, values were 8/202 (4.0%) versus 13/189 (6.9%), 
mean difference = -2.9% (95% CI -7.4% to 1.6%, p=0.20); at 6 weeks values were 86/193 
(44.6%) versus 80/181 (44.2%); mean difference = 0.4% (95% CI -9.7% to 10.4%, p=0.94); 
and at 8 weeks values were 121/196 (61.7%) versus 103/183 (56.3%); mean difference = 
5.4% (95% CI -4.5% to 15.3%; p=0.28).  All fractures in both groups had healed at 24 weeks.  
A time-to event analysis demonstrated no difference between the groups in fracture healing 
(supplementary Figure 1).  Further detail on endosteal healing, trabecular bridging and the 
number of cortices bridged at each time point are shown in supplementary Table 1.  
Secondary outcomes  
Patient reported outcome 
The change over time of pain at the fracture site and the DASH score are shown in Figure 3. 
The DASH score decreased with time reflecting improvement in upper limb function and there 
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was no significant difference between the groups at any point (Figure 3A). Pain at the fracture 
site decreased with time following the fracture but there was no significant difference 
between the treatment groups at any time point (Figure 3B). Additional analyses of pain score 
and DASH score using multiple imputation demonstrated no significant differences between 
groups (Supplementary Table 2). There was no significant difference between treatment 
groups in grip strength at 8 or 26 weeks or the range of wrist movement at 26 weeks 
(Supplementary Table 2).  
Adverse events and other fracture outcomes 
Data on adverse events and fracture related outcomes are summarised in Table 2. The 
proportion of patients with adverse events and serious adverse events was similar in both 
groups.  No suspected unexpected serious adverse reactions were reported in either group.  
The rate of malunion was 34.3% (n=130) with no significant difference between groups.  The 
overall incidence of CRPS was low (0.8%, n=3) and did not differ significantly between groups.   
DISCUSSION 
The FAB study is the first parallel group randomised controlled trial to directly investigate the 
effects of a bisphosphonate on fracture union. We found no statistically significant difference 
in the proportion of patients with a united fracture at any time point, and at the primary time 
point of 4 weeks, the 95% confidence interval for the difference in the proportions with a 
united fracture excluded a difference as large as 15%. In keeping with the lack of a significant 
effect on fracture union, we observed no difference in other patient-reported outcomes such 
as the patient reported DASH score, pain at the fracture site, grip strength, other fracture 
related outcomes or in adverse events.  The lack of a difference between groups cannot be 
attributed to differences in adherence to medication, which was greater than 85% in both 
treatment arms.  
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The main strength of this study is that it is the first randomised double-blind controlled 
study on the effect of a bisphosphonate on radiological fracture healing. Although we used 
distal radius fractures as a model to investigate this issue as it is recognised as the most 
common incident fracture, the fundamental processes of healing are analogous in all fracture 
types and it is probable that the results of this trial may apply to other fractures as well.  
However, further studies will likely be required to determine to what extent the results may 
be generalizable to other fracture types.  Another limitation of the trial is that due to the 
nature of the study design, we are unable to comment on the long-term effects of 
bisphosphonate therapy on fracture healing.  
Bisphosphonates have potent inhibitory effects on bone remodelling, and because of 
this, concerns have been raised that they may inhibit fracture union(5). Preclinical studies have 
been reassuring in showing that bisphosphonates do not impair fracture healing and actually 
increase the size and mineralisation of fracture callus(4). Clinical studies which have 
investigated the effects of bisphosphonates on fracture healing have yielded conflicting 
results.  A systematic review by Molvik and Khan(5) identified five observational studies in 
which the time to fracture healing had been assessed in bisphosphonate-treated patients as 
compared with controls who had not received bisphosphonates.  This found that there was 
delayed union of wrist fractures in bisphosphonate treated patients but that there was no 
difference for femoral fractures(5).  The effects of bisphosphonates on fracture healing has 
previously been investigated in three small randomized trials all of which used a sequential 
design. One was an open study of patients with distal radius fractures treated by internal 
fixation with locking plates in which 24 patients were randomized to receive 70mg oral 
alendronic acid within 2 weeks of the fracture and a further 26 subjects were randomised to 
receive alendronate three months after the fracture (19). The mean union time in each group 
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was 6.7 and 6.8 weeks respectively, a difference that was not significant.  A further 
prospective randomised trial including fractures of the distal radius treated managed with a 
volar locked plating, randomized 40 subjects to receive alendronic acid within a few days of 
surgery and a further 40 to receive alendronic acid four months after surgery(20).  No 
significant difference in time to fracture union was observed between the groups (3.5 vs 3.1 
months). A final third randomised trial investigated the effects of administering oral 
risedronate sodium 35mg weekly within one week, one month or three months of the injury 
in patients with femoral intertrochanteric fractures(21). No significant differences were found, 
but only 25-26 subjects were included per treatment group.  
The effects of zoledronic acid on delayed union and non-union were evaluated in a 
secondary analysis of the HORIZON-RFT trial which involved 2127 patients with hip fracture 
treated with zoledronic acid or placebo(22). The authors did not formally assess time to 
fracture union in this study but compared the proportion of patients with delayed union in 
each group. In this study delayed union was defined as being present if the patient had clinical 
symptoms to suggest the fracture had not united 6 weeks after the injury and there were 
radiographic findings of delayed union. Using this definition, 3.2% of the zoledronic acid group 
had delayed union compared with 2.7% of the placebo group, a difference that was not 
significant (odds ratio 1.17, 95% CI 0.72-1.90, p=0.61). The effects of alendronic acid on bone 
density at the wrist (23) and of clodronate on density of fracture callus(24) have also been 
evaluated in patients with wrist fracture but neither of these studies assessed fracture union.  
The results of this study have important clinical implications as many physicians and 
orthopaedic surgeons delay administration of bisphosphonates following a fracture because 
of concerns that they may impair healing.  Such delay could place patients at risk of a second 
 
 14 
fracture, which frequently occurs within the first few months after an incident fracture (8,25-27) 
The clinical importance of this study is that it demonstrates that oral bisphosphonate therapy 
can be safely administered within a week or two following a fracture, without adversely 
affecting clinical outcome. Although the study was not designed to evaluate whether early 
initiation of treatment is superior to delayed treatment, one would assume that earlier 
treatment would be beneficial in preventing a second fracture in this high-risk group. 
We acknowledge that the FAB study has other limitations.  We addressed the issue of 
whether early administration of bisphosphonate inhibits fracture union in patients who are 
treatment naïve and the results may not be applicable to patients who fracture when they 
are already taking bisphosphonates. Further studies will be required to determine whether 
long-term bisphosphonate therapy in this patient group inhibits or delays fracture union.  
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Table 1:  Demographic and clinical characteristics at baseline by randomization group. 
 Alendronic acid 
(n=215) 
Placebo 
(n=206) 
Age (yrs) 63 ± 8.5 63. ± 8.5 
Female Gender 186 (86.5%) 176 (85.4%) 
Smoker 28 (13.0%) 28 (13.6%) 
Alcohol consumption 6.8 ± 8.7 7.2 ± 8.7 
Co-morbidities 
Cardiovascular disease  15 (7.0%) 4 (2%) 
COPD 24 (11.2%) 20 (9.7%) 
Chronic liver disease 2 (1%) 5 (2.4%) 
Diabetes  12 (5.6%) 8 (3.4%) 
Previous malignancy 10 (4.6%) 16 7.8%) 
Charlson Index Score 0.4 ± 0.7 0.4 ± 0.9 
Bone active medications 
Any bone medication 60 (27.9%) 61 (29.6%) 
Systemic glucocorticoids   14 (6.5%) 12 (5.8%) 
Bisphosphonates 1 (0.5%) 2 (1.0%) 
Teriparatide 2 (0.9%) 0 (0%) 
HRT 22 (10.2%) 33 16.0%) 
Other 2 (1.8%) 0 (0%) 
Calcium and/or vitamin D 48 (22.3% 42 (20.4%) 
Fracture Characteristics 
Right sided fracture 97 (45.1%) 87 (42.2%) 
Right side dominant hand   188 (87.4%) 186 (90.3%) 
Displaced fracture 125 (58.1%) 120 (58.3%) 
Extra-articular fracture 137 (63.7%) 131 (63.3%) 
Partial articular fracture 74 (34.4%) 70 (34%) 
Complete articular fracture 4 (1.9%) 5 (2.4%) 
Comminuted fracture 131 (62.1%) 118 (58.7%) 
Dorsal angulation (degrees) 11.9 ± 17.6 11.8 ± 17.4 
Ulnar variance (mm) 2.1 ± 2.5 2.0 ± 2.5 
Carpal malalignment 119 (56.4%) 107 (53.2%) 
Fracture Management 
Cast  168 (78.1%) 159 (77.2%) 
MUA and K-wires 2 (0.9%) 8 (3.9%) 
External fixation 10 (4.7%) 7 (3.4%) 
ORIF 35 (16.3%) 32 (15.5%) 
Pre-injury DASH score 7.9 ± 14.6 7.8 ± 14.7 
Data on comminution, dorsal angulation, and carpal malalignment were available in 211 of 
the alendronate group and 201 of the placebo group. Data on ulnar variance were available 
in 211 of the alendronate group and 200 of the placebo group. (MUA = manipulation under 
anaesthesia; ORIF = open reduction internal fixation). For prior bone active medications 
values add up to greater than 100% since some patients received more than one drug.    
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Table 2:  Fracture outcomes and adverse events by randomization group. 
 Alendronic acid 
(n=215) 
Placebo 
(n=206) 
Malunion 70 (35.5%) 60 (33.0%) 
Dorsal angulation (mm) 2.65 ± 13.3 3.68 ± 13.0 
Ulnar variance (mm) 2.14 ± 2.3 2.1 ± 2.1 
Carpal malalignment 72 (36.5%) 62 (34.1%) 
CRPS 1 (0.5%) 2 (1.1%) 
Adverse events  220 215 
Serious adverse events  6 4 
 
The data shown are from the end of study visit at 26 weeks. The values are numbers (%) or 
mean ± SD. Information on malunion, dorsal angulation, ulnar variance and carpal 
malalignment was available for 197 subjects in the alendronic acid arm and 182 subjects in 
the placebo arm. Information on chronic regional pain syndrome (CRPS) was available in 198 
subjects in the alendronic acid arm and 182 subjects in the placebo arm.  
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Figure 1:  Disposition of study subjects. 
 
  
 
*Details of the other reasons for non-enrolment are shown in supplementary Table 3  
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Figure 2: Fracture healing by randomization group.  
 
The proportions of patients with a united fracture at each time point are shown. There was 
no significant difference between the groups at any time point. 
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Figure 3: Effects of treatment on DASH and pain scores. 
 
Panel A shows the effects of treatment on the DASH score and panel B on pain score at the 
fracture site as assessed by visual analogue scale. Columns are means and bars are standard 
deviation. There was no significant difference between the groups at any time point. 
